Comparison
Armodafinil vs Selank
Side-by-side of Armodafinil and Selank. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Armodafinil
Armodafinil is the R-enantiomer sold as Nuvigil. Half-life 10-15 h, 150 mg standard dose, narcolepsy and shift-work approvals, Schedule IV.
Selank
Selank peptide benefits: tuftsin analog heptapeptide, intranasal anxiolytic and nootropic. Russian clinical data, dosing, half-life, safety.
Effects at a glance
Armodafinil
- •FDA approved in 2007 for narcolepsy, shift-work sleep disorder, and OSA residual sleepiness
- •R-enantiomer of modafinil; 150 mg armodafinil is roughly equivalent to 200 mg modafinil
- •Schedule IV controlled in the US; prescription-only globally
- •Longer terminal half-life of about 15 hours produces extended late-day wakefulness coverage
- •Same CYP3A4 induction as modafinil; reduces hormonal contraceptive efficacy
- •Side-effect profile and dermatologic risk warnings mirror modafinil
Selank
- •Synthetic heptapeptide analog of tuftsin developed in Russia in the 1990s
- •Approved in Russia for generalized anxiety disorder and asthenic conditions
- •Russian RCTs report anxiolytic effects comparable to medazepam without sedation or dependence
- •Modulates GABAergic and serotonergic signaling and BDNF expression in preclinical models
- •Most commonly administered intranasally; subcutaneous use is anecdotal
- •No Western-validated trials; not FDA approved; research-use-only outside Russia
Side-by-side
| Attribute | Armodafinil | Selank |
|---|---|---|
| Category | pharmaceutical | peptide |
| Also known as | Nuvigil, R-modafinil, (R)-(-)-modafinil | TP-7, Tuftsin analog |
| Half-life (hr) ↗ | 15 | 0.5 |
| Typical dose (mg) ↗ | 150 | 0.4 |
| Dosing frequency | daily, morning | 2-3x daily (intranasal) |
| Routes | oral | intranasal, subcutaneous |
| Onset (hr) | 1 | 0.25 |
| Peak (hr) | 3 | 1 |
| Molecular weight | 273.35 | 751.85 |
| Molecular formula | C15H15NO2S | C33H57N11O9 |
| Mechanism | Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake systems; R-enantiomer of modafinil with longer half-life. | Modulates GABAergic, serotonergic, and dopaminergic signaling. Increases BDNF expression in hippocampal neurons in preclinical models. Modulates enkephalin levels and immune cytokine signaling via tuftsin-like activity. |
| Legal status | Schedule IV (US); prescription-only globally; not a supplement | Approved as a prescription anxiolytic in Russia; not FDA approved; research-use-only grey market in most other jurisdictions |
| WADA status | banned | unknown |
| DEA / Rx | Schedule IV | Not FDA approved; not scheduled; research-chemical status outside Russia |
| Pregnancy | Not recommended | Not recommended; insufficient data |
| CAS | 112111-43-0 | 129954-34-3 |
| PubChem CID | 9148206 | 11765600 |
| Wikidata | Q4791953 | Q4416793 |
Safety profile
Armodafinil
Common side effects
- headache
- nausea
- dizziness
- anxiety
- insomnia (with later-day dosing)
- dry mouth
- mild blood pressure elevation
Contraindications
- recent myocardial infarction
- unstable angina
- left ventricular hypertrophy
- significant arrhythmia
- history of Stevens-Johnson syndrome
- psychotic disorders
- pregnancy
- concurrent MAOI use
Interactions
- hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
- cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
- warfarin: CYP2C9 inhibition raises INR(moderate)
- phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
- MAOIs: potential hypertensive reaction(major)
- classical stimulants: additive cardiovascular and sleep-disruption effects(moderate)
Selank
Common side effects
- mild nasal irritation (intranasal)
- transient drowsiness (uncommon)
- mild headache
Contraindications
- pregnancy
- lactation
- severe psychiatric disorder (insufficient data)
Interactions
- benzodiazepines: additive anxiolytic effect; potential for over-sedation when stacked(moderate)
- SSRIs: no documented adverse interaction; co-administration described in Russian protocols(minor)
Which Should You Take?
Armodafinil comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Selank is the right call when one of the conditionals below applies.
- → If your priority is wakefulness, pick Armodafinil.
- → If your priority is fatigue resistance, pick Armodafinil.
- → If your priority is anxiety reduction, pick Selank.
- → If your priority is mood, pick Selank.
Edge case: If you cannot self-administer injections, Armodafinil is the only oral option in this pair.
Default choice: Armodafinil. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Selank only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Armodafinil and Selank?
Armodafinil and Selank differ in category (pharmaceutical vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Armodafinil or Selank?
Armodafinil half-life is 15 hours; Selank half-life is 0.5 hours.
Can you stack Armodafinil with Selank?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper